Nature Communications

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)

2026-02-16

Full text

DOI https://doi.org/10.1038/s41467-026-69222-5